Fact Sheets

Press Releases

Archived Press Releases

2007

BDSI Exercises Option to Acquire U.S. BEMA™ Rights (September 10, 2007)
BDSI Secures U.S. Commercial Partnership for BEMA™ Fentanyl with Meda AB (September 5, 2007)
BDSI Names David Blum, M.D. Vice President of Medical Affairs and Clinical Research (August 14, 2007)
BEMA™ Fentanyl NDA Submission Remains on Target for Third Quarter Following Meeting With FDA (July 2, 2007)
BDSI Joins Russell Microcap Index (June 26, 2007)
BDSI to Voluntarily Withdraw Boston Stock Exchange Listing (June 22, 2007)
BDSI Announces Positive Key Secondary Efficacy Endpoint Results For BEMA™ Fentanyl (May 14, 2007)
BEMA™ Fentanyl Demonstrates Substantial Transmucosal Delivery In Absolute Bioavailability Study (May 7, 2007)
BDSI Announces Positive Phase III Clinical Trial Results for BEMA™ Fentanyl (April 25, 2007)
BioDelivery Sciences Names Al Medwar as Vice President of Marketing (April 10, 2007)
BDSI to Present on BEMA™ Fentanyl at American Society of Clinical Pharmacology and Therapeutics 2007 Annual Meeting (March 21, 2007)
BDSI to Present on BEMA Fentanyl at Oppenheimer Pain Conference (March 2, 2007)
BDSI Anticipates Announcing Phase III BEMA Fentanyl Efficacy Data in April (February 8, 2007)
BDSI Announces FDA Acceptance of Bioral® Amphotericin IND (February 2, 2007)
Hopkins Capital Group II Converts BDSI Series B Preferred Stock at $4.25 per Share (January 12, 2007)

2006

BDSI to Present at The PIPEs Conference 2006 at the Waldorf Astoria, New York City, November 7-8, 2006 (November 6, 2006)
BDSI Receives Approval to Restart BEMA™ Fentanyl Trials in California (September 26, 2006)
Following FDA Meeting BDSI Projects Submission of BEMA™ Fentanyl NDA in Second Quarter 2007 (September 20,2006)
BioDelivery Sciences Claims Recent Actions by Clinical Development Capital Undermine All Other Stockholders’ Interests (September 5, 2006)
BioDelivery Sciences Appoints Thomas W. D'Alonzo to Board of Directors (August 30, 2006)
BioDelivery Sciences Mourns the Loss of Revered Board Member Bill Stephenson (August 29, 2006)
BEMA™ LA Achieves Therapeutic Plasma Concentrations in Phase I Trial: Complementary Pain Therapy to Phase III BEMA™ Fentanyl Product (August 16, 2006)
Study Shows Bioral® Delivery Technology Delivers Influenza siRNA Therapeutic and Reduces Virus Levels by 200 times in Mice (August 9, 2006)
BioDelivery Sciences International and MEDA AB Announce European Licensing Agreement on BEMA™ Fentanyl (August 3, 2006)
BDSI Announces Purchase of Non-U.S. BEMA™ Technology from QLT USA, Inc. (August 3, 2006)
BDSI Submits Two Emezine® Pharmacokinetic Study Designs to the FDA Under Special Protocol Assessment (July 17, 2006)
BioDelivery Sciences Announces Promising Results of Meeting With FDA On Emezine® (June 09, 2006)
BioDelivery Sciences Demonstrates Multiple Dose Linearity with BEMA™ Fentanyl (May 22, 2006)
BioDelivery Sciences Closes $7 Million Value Transaction with Clinical Development Capital, LLC (May 17, 2006)
BioDelivery Sciences Confirms Dose Proportionality with BEMA™ Fentanyl (April 24, 2006)
BioDelivery Sciences Announces Year End Results (March 31, 2006)
BioDelivery Sciences Updates Product Development Pipeline Status and 2006 Milestones (March 14, 2006)
BioDelivery Sciences to Host Conference Call to Discuss Emezine® Status and Provide Update on Product Development Pipeline (March 3, 2006)
BioDelivery Sciences Receives Non-Approvable Notification from FDA on Emezine® (March 1, 2006)
BioDelivery Sciences Receives Initial $2 Million Payment from CDC for Development of BEMA(TM) Fentanyl (February 16, 2006)
BioDelivery Sciences Retains Addison Whitney as Brand Development Firm for BEMA™ and BEMA™ Fentanyl (February 2, 2006)
BioDelivery Sciences Retains The Investor Relations Group of New York (January 13,2006)
BioDelivery Sciences Hires Proven Pharmaceutical Executive To Head Sales and Marketing Effort (January 9, 2006)
BioDelivery Sciences Files IND for BEMA LA, a Treatment for Moderate to Severe Pain (January 6, 2006)

2005

New Study Shows BDSI's Emezine(R) Demonstrates More Efficient Absorption (December 7, 2005)
BDSI Announces its Intention to Proceed with Phase III Trials in 2006 on its Second BEMA(TM) Product (November 28, 2005)
BioDelivery Sciences International to Present at Wall Street Analyst Forum (November 21,2005)
BDSI Announces Supply Agreement Relating to BEMA(TM) Fentanyl (November 8, 2005)
BDSI Prepares For Phase III with BEMA(TM) Fentanyl Following Positive Results (November 1, 2005)
BDSI Closes Public Offering of 4.4 Million Shares (October 5, 2005)
BDSI Prices Public Offering of 4.4 Million Shares (September 30, 2005)
BDSI Announces Director Resignations (September 16, 2005)
BDSI Names Mark Sirgo as Chief Executive Officer (August 23, 2005)
BDSI Announces Acceptance of Emezine(R) NDA for Review By FDA (July 20, 2005)
BDSI Secures $7 Million Financing Commitment For Development of BEMA(TM) Fentanyl (July 18, 2005)
BDSI Secures Additional $2.5 Million Financing With Laurus Master Fund (June 3, 2005)
BDSI Announces Submission of NDA for Emezine (May 2, 2005)
William S. Poole Appointed to BDSI Board (April 29, 2005)
BDSI Announces Relocation of its Corporate Headquarters (March 28, 2005)
Expediting Drug Development Using Patented Drug Delivery Technologies (March 23, 2005)
BDSI Announces Its Intention to Initiate Phase III Clinical Trials of BEMA Fentanyl (March 07, 2005)
BDSI Secures $2.5 Million Financing With Laurus Master Fund (February 23, 2005)
BDSI Completes Clinical Trials for its Formulation of Emezine(February 9, 2005)
Sirgo Appointed President of BDSI (January 31, 2005)
BDSI Announces Agreement to License its Nanocochleate Delivery Technology to Sigma-Tau (January 20, 2005)
BDSI's Bioral Drug Delivery Technology May Reduce GI Damage Caused By NSAIDs and Aspirin (January 4, 2005)

2004

Bioral™ Delivery Technology may reduce GI Toxicity of NSAIDS and Aspirin without Dependence on Selective COX-2 Inhibitors (December 22, 2004)
BDSI to Continue Listing on Nasdaq Small Cap Market (December 1, 2004)
BDSI Reports Financial Results for the Third Quarter Ended September 30, 2004 (November 12, 2004)
BDSI Granted NASDAQ Exception for Continued Listing on the Small Cap Market (October 14, 2004)
BDSI Announces Letter of Intent for License of its Nanocochleated Delivery Technology with Sigma-Tau and Receipt of Initial $250,000 Deposit (September 27, 2004)
BDSI Elevates Sirgo and Finn to New Positions (September 14, 2004)
BDSI Announces $2,500,000 Asset Sale to Accentia (September 8, 2004)
BDSI Announces Final Equity Line of Credit Agreement (September 7, 2004)
BDSI Announces New Agreement with Hopkins Capital Group (August 24, 2004)
BDSI Announces the Closing of the Arius Pharmaceuticals Acquisition (August 24, 2004)
BDSI Announces the Acquisition of Arius Pharmaceuticals, Inc. (August 10, 2004)
BDSI Receives NASDAQ Delisting Notice and will Appeal (August 3, 2004)
BDSI Announces $4,000,000 Credit Facility (August 3, 2004)
BDSI Announces Proposed Licensing Agreement with Sigma-Tau S.p.A. (July 28, 2004)
Wall Street Journal Reports BDSI Enters into Licensing Agreement for Topical Version of Amphotericin B (July 14, 2004)
BDSI at the Milano Tech 2004 Technology Partnering Conference Milano, Italy – May 19-20, 2004 (May 12, 2004)
BDSI at Nanobiotech Conference in San Francisco (April 15, 2004)
BDSI Announces Licensing of its Topical BioNasal™ Amphotericin B for Chronic Sinusitis (April 13, 2004)
BDSI Announces Participation at the Nanobiotech Conference in San Francisco (April 6, 2004)
BDSI Reports 2003 Results (April 6, 2004)
BDSI in Exclusive Negotiations with Affiliate of Italy’s Sigma-Tau to Formulate New Type of Aspirin (February 11, 2004
BDSI Updates Public on Spin Off Subsidiary (January 16, 2004)

2003

BDSI Announces Agreement with Defiante Farmaceutica Lda (December 3, 2003)
BDSI to Establish Israeli Subsidiary to Develop Oral Enzyme Replacement for Gauchers Disease (November 24, 2003)
BDSI Announces Plans to Distribute Interests in Food Processing and Personal Care Product Subsidiary to Stockholders (November 19, 2003)
BDSI to Participate in BioMilano 2003 (November 11, 2003)
New Biogeode Cochleates could make Healthy Nutrients more Available in Processed Foods (September 30, 2003)
Bioral™ Pharmaceutical Delivery System Improves Efficacy and Reduces Side Effects of Aspirin (September 23, 2003)
BDSI Formulates Omega-3 Fatty Acids as Stable, Dry Powder Using its Bioral Nanotechnology (June 30, 2003)
BDSI Announces Common Stock Repurchase Program (April 2, 2003)
BDSI Reports 2002 Results (April 1, 2003)
BDSI Announces Formation of Subsidiary to Develop Opportunities in the Processed Food and Beverage Sectors (February 26, 2003)
BDSI Announces Licensing Agreement with PPD (January 6, 2003)